Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
•Development of lead drug candidate NYR-BI03 continues:
-Phase I clinical trial commenced with first cohort dosing completed and second cohort recruitment in train.
-Collaborative TBI study with WRAIR and UNSW reported NYR-BI03 demonstrated statistically significant neuroprotection.
-Preliminary international patent search has affirmed the novelty and inventiveness of NYR-BI03.

•Sound financial and strategic position:
-Cash position of AU$4.76 million at 31 March 2025.